Comparison between mefenamic acid and danazol in the treatment of established menorrhagia.
Forty women with established menorrhagia were treated with either mefenamic acid (500 mg thrice daily for 3-5 days in two cycles) or danazol (100 mg twice daily for 60 days) in an open parallel group randomized study. Mefenamic acid reduced mean menstrual blood loss from 160 ml to 127 ml (20%, P less than 0.01). Danazol reduced mean menstrual loss from 163 ml to 65 ml (60%, P less than 0.001). The percentage reduction in menstrual blood loss was significantly greater in the danazol group than in the mefenamic acid group, but the adverse side-effects occurred significantly more often in the danazol group (75%) than in the mefenamic acid group (30%, P less than 0.005). Overall, approximately half the women in each group were prepared to continue with the treatment they received to reduce their menstrual bleeding.
Dockeray
C J
CJ
Trinity College Department of Obstetrics and Gynaecology, Sir Patrick Dun Research Laboratory, St James's Hospital, Dublin, Ireland.
Sheppard
B L
BL
Bonnar
J
J
D000328:Adult; D003613:Danazol / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008528:Mefenamic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D008595:Menorrhagia / Q000188:drug therapy*; D008875:Middle Aged; D010349:Patient Compliance; D011245:Pregnadienes / Q000627:therapeutic use*; D011897:Random Allocation
D011245:Pregnadienes; D008528:Mefenamic Acid; D003613:Danazol